Journal
CURRENT MEDICINAL CHEMISTRY
Volume 27, Issue 37, Pages 6356-6372Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867326666190730113123
Keywords
Osteoporosis; osteoimmunology; bone remodeling; cytokines; immunological checkpoints; biological therapies
Ask authors/readers for more resources
Osteoporosis is a skeletal pathology characterized by compromised bone strength leading to increased risk of fracture, mainly the spine and hip fractures. Osteoporosis affects more than 200 million people worldwide and because of the skeletal fractures it causes, represents a major cause of morbidity, disability and mortality in older people. Recently, the new discoveries of osteoimmunology have clarified many of the pathogenetic mechanisms of osteoporosis, helping to identify new immunological targets for its treatment opening the way for new and effective therapies with biological drugs. Currently, there are basically two monoclonal antibodies for osteoporosis therapy: denosumab and romosozumab. Here, we focus on the modern approach to the osteoporosis management and in particular, on current and developing biologic drugs targeted to new immunological checkpoints, in the landscape of osteoimmunology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available